Current Treatment Options in Oncology最新文献

Advances in PSMA-Targeted Radionuclide Therapeutics.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-26 DOI: 10.1007/s11864-025-01296-7

Samuel Ruder, Andres Ricaurte-Fajardo, Michael Sun, Sandra Huicochea Castellanos, Joseph R Osborne, Scott T Tagawa

{"title":"Advances in PSMA-Targeted Radionuclide Therapeutics.","authors":"Samuel Ruder, Andres Ricaurte-Fajardo, Michael Sun, Sandra Huicochea Castellanos, Joseph R Osborne, Scott T Tagawa","doi":"10.1007/s11864-025-01296-7","DOIUrl":"https://doi.org/10.1007/s11864-025-01296-7","url":null,"abstract":"Opinion statement: Prostate-specific membrane antigen targeted radionuclide therapies (PSMA-TRT) such as 177Lu-PSMA-617 hold great promise in improving clinical outcomes at various stages of prostate cancer. The FDA approval of 177Lu-PSMA-617 represents a significant advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated improved radiographic progression-free survival (rPFS) and overall survival (OS) with 177Lu-PSMA-617 in patients with mCRPC who had already receive androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy. Exploration of 177Lu-PSMA-617 in earlier stages of prostate cancer, such as in the PSMAfore trial for patients who have not received chemotherapy, holds great promise for improving long-term outcomes and delaying exposure to chemotherapy. Combining 177Lu-PSMA-617 with other therapies, including chemotherapy, PARP inhibitors, and immunotherapy, is an area of active investigation. This review will also discuss alternative radionuclides (such as actininum-225 and terbium-161) and delivery vehicles (such as PSMA-I&T), which we find promising. Predictive biomarkers and dosimetry will be crucial for identifying patients most likely to benefit from PSMA-TRT. Continued research and refinement of these therapies will lead to PSMA-targeted treatments becoming an integral part of prostate cancer management.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the Therapeutic Potential of Natural Polyphenols in Esophageal Cancer.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-22 DOI: 10.1007/s11864-025-01308-6

Chengu Niu, Jing Zhang, Patrick I Okolo

{"title":"Unlocking the Therapeutic Potential of Natural Polyphenols in Esophageal Cancer.","authors":"Chengu Niu, Jing Zhang, Patrick I Okolo","doi":"10.1007/s11864-025-01308-6","DOIUrl":"https://doi.org/10.1007/s11864-025-01308-6","url":null,"abstract":"Opinion statement: Esophageal cancer (EC), one highly malignant upper gastrointestinal cancer, is the eighth most commonly occurring cancer and the sixth leading cause of cancer-related deaths worldwide. Clinically, this malignancy is considered to be one of the most difficult-to-treat cancers, owing to its resistance to common therapies like chemotherapy and radiotherapy, and few targeted therapies are available. There is currently an unmet need for treatment of EC. Polyphenols are naturally occurring plant secondary metabolites in response to environmental threats and injury. Epidemiological evidence suggests that long-term consumption of a polyphenol-rich diet is inversely associated with the risk of cancer. Currently, natural polyphenols have received increased attention for their potential therapeutic effects on EC. In this review, we summarize and discuss recent progress in the therapeutic potential of natural polyphenols in EC, as well as their sources, oral bioavailability, and pharmacokinetics. We review natural polyphenols combined with approved chemotherapy and radiotherapy to overcome challenges faced by either monotherapy. We also discuss the current challenges and future directions to accelerate the clinical application of natural polyphenols in EC. We concluded that natural polyphenols represent promising candidates for the management of EC. Well-designed randomized controlled studies are warranted to verify the efficacy and safety of natural polyphenols for EC. Knowledge gained from this review will outline possible future research directions and should help to develop new therapeutics for this disease.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Minimal Residual Disease in Metastatic Soft Tissue Sarcoma.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-12 DOI: 10.1007/s11864-025-01303-x

Ioannis Kournoutas, Brittany L Siontis

{"title":"Minimal Residual Disease in Metastatic Soft Tissue Sarcoma.","authors":"Ioannis Kournoutas, Brittany L Siontis","doi":"10.1007/s11864-025-01303-x","DOIUrl":"https://doi.org/10.1007/s11864-025-01303-x","url":null,"abstract":"Opinion statement: Liquid biopsies represent a promising and minimally invasive approach to diagnosing and monitoring cancer. In recent years, studies across a multitude of solid organ malignancies have suggested the clinical utility of biomarkers such as circulating tumor DNA (ctDNA). Particular attention has been given to serial assessment of such biomarkers in an effort to detect minimal residual disease (MRD), in order to predict which patients may be at highest risk of relapse following curative-intent surgical or medical intervention. Such investigations are particularly relevant to sarcomas, which are highly heterogeneous malignancies and commonly develop treatment resistance. While preliminary research described herein is promising, there remain key barriers to widespread adoption of liquid biopsy in sarcoma, including the lack of standardized detection methods, high cost, and the need for large, prospective studies to validate their clinical utility. Given the high level of interest in liquid biopsy in the biomedical community, it is plausible such obstacles may be overcome in the near future. With such advancements, one can anticipate that liquid biopsies may become a key tool in the sarcoma oncologists armamentarium, and offer a path toward improved outcomes for patients with sarcoma.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiosarcoma: Role of Immunotherapy.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-08 DOI: 10.1007/s11864-025-01307-7

Tom Wei-Wu Chen

{"title":"Angiosarcoma: Role of Immunotherapy.","authors":"Tom Wei-Wu Chen","doi":"10.1007/s11864-025-01307-7","DOIUrl":"10.1007/s11864-025-01307-7","url":null,"abstract":"Opinion statement: Recent clinical trials have investigated immune checkpoint inhibitors (ICIs) alone, in combination with tyrosine kinase inhibitors (TKIs), or with chemotherapy in angiosarcoma, yielding mixed results across subtypes. Single-agent ICI therapy, such as cemiplimab (ORR 27.8%), has shown responses primarily in UV- and radiation-associated angiosarcomas, likely due to their higher tumor mutation burden (TMB), while dual ICI therapy (SWOG S1609, ORR 25%) suggests potential benefit but remains limited in cutaneous disease. ICI-TKI combinations, such as cabozantinib plus nivolumab (Alliance A091902, second-line, ORR 59%), demonstrated significant efficacy in both cutaneous and non-cutaneous angiosarcomas, suggesting anti-angiogenic therapy may enhance ICI responses in tumors historically resistant to checkpoint blockade. ICI-chemotherapy combinations have been less consistent. The Alliance A091902 first-line trial (paclitaxel ± nivolumab) found no overall PFS benefit, though scalp/face angiosarcoma patients appeared to fare better, raising the question of whether ICI alone might be equally effective in this subset. The South Korean paclitaxel + avelumab trial (ORR 50%) showed promising response rates, but the lack of detailed subgroup analysis limits interpretation. Other chemotherapy-ICI combinations, such as doxorubicin plus pembrolizumab, have shown isolated responses but require further study in larger cohorts. Moving forward, better biomarkers are critical for identifying which patients benefit most from ICIs, and while TKI-ICI combinations appear to hold the most promise, chemotherapy-ICI strategies need further refinement to optimize sequencing and patient selection in angiosarcoma treatment.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients. 针对胃癌患者的 HER2 靶向疗法不断发展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-08 DOI: 10.1007/s11864-025-01300-0

Lijuan He, Ben Liu, Zhuanfang Wang, Qinying Han, Hao Chen

{"title":"Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.","authors":"Lijuan He, Ben Liu, Zhuanfang Wang, Qinying Han, Hao Chen","doi":"10.1007/s11864-025-01300-0","DOIUrl":"10.1007/s11864-025-01300-0","url":null,"abstract":"Opinion statement: Gastric cancer (GC) is a deadly disease worldwide, and trastuzumab in combination with chemotherapy has been the standard first-line treatment for HER2-positive GC following the TOGA trial. Besides adjuvant therapy, HER2-directed therapy is widely used as neoadjuvant or translational therapy, and survival benefit even surgical opportunities is seen in these patients. However, resistance is not rare in recent years, and the second-line treatment for trastuzumab beyond progression has received widespread attention in GC. Moreover, current evidence cannot recommend trastuzumab for patients with IHC1+ HER2 low expression GC yet. Researchers are currently investigating whether GC patients with low HER2 expression could also benefit from HER2-directed therapies. In addition to using HER2 as a target for targeted therapy, HER2-mediated targeted delivery of cytotoxic drugs and targeted immunity have made important contributions to overcoming trastuzumab resistance in recent trials. HER2/neu-derived peptide epitopes vaccination and HER2-specific chimeric antigen receptor (CAR) therapy focus on reestablishing anti-tumor immunity in different ways and show significant anti-tumor activity. Other antibodies that target different regions of the HER2 receptor or block key downstream pathways such as AKT or PI3K also offer potential anti-tumor activity against HER2. HER2 use in GC will not be hampered by resistance or low expression and will play a bigger role. We review the current efforts to enable GC patients with trastuzumab-resistant and HER2 low-expressing accessible to HER2 targeted therapy and present our consideration for future HER2 in GC.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-06 DOI: 10.1007/s11864-025-01304-w

Demitrios Dedousis, Elyse Gadra, Joseph Van Galen, Margaret von Meren

{"title":"Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies.","authors":"Demitrios Dedousis, Elyse Gadra, Joseph Van Galen, Margaret von Meren","doi":"10.1007/s11864-025-01304-w","DOIUrl":"https://doi.org/10.1007/s11864-025-01304-w","url":null,"abstract":"Opinion statement: Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal soft tissue sarcomas, with an incidence of about 15 cases per million person-years. Approximately 15% of GIST develop due to succinate dehydrogenase deficiency (SDH-Def), and such tumors do not respond well to the tyrosine kinase inhibitors (TKIs) used to treat other GIST. Due to its indolent nature SDH-Def GIST can often be surveilled if asymptomatic. In our current practice we typically treat advanced symptomatic SDH-Def GIST with the anti-angiogenic TKIs, sequentially treating with sunitinib, regorafenib and pazopanib. This practice is based on limited data. This systematic review provides an update on new data (12/21/2021 to 9/26/2024) for systemic treatment of SDH-Def GIST, both with agents generally used to treat other GIST subtypes and with agents approved in other malignancies. Olverembatinib and rogaratinib have shown promising activity in pre-clinical models and small SDH-Def GIST cohorts. Other agents whose benefits are explored here include the immune checkpoint inhibitors (ICI) ipilimumab and nivolumab and temozolomide, whether as monotherapy or in combination with INBRX-109 (a pro-apoptotic antibody) or olaparib. Additional research into TKI agents with anti-vascular endothelial growth factor receptor (VEGFR) and anti-fibroblast growth factor receptor (FGFR) activity in this clinical setting is needed. Patients with SDH-Def will benefit more broadly from ongoing explorations of treatments with alternative mechanisms of action, especially those that exploit cellular pathways involved in SDH-Def GIST tumorigenesis.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-05 DOI: 10.1007/s11864-025-01295-8

Fatemeh Karimi, Mojtaba Aghaei, Najmaldin Saki

引用次数: 0

Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI: 10.1007/s11864-025-01302-y

Yoshitaka Saito

{"title":"Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management.","authors":"Yoshitaka Saito","doi":"10.1007/s11864-025-01302-y","DOIUrl":"10.1007/s11864-025-01302-y","url":null,"abstract":"Opinion statement: Taxane-associated acute pain syndrome (T-APS) is one of the most common adverse effects of taxane treatment and significantly reduces the quality of life and activities of daily living of patients. T-APS is recognized as myalgia and arthralgia, which generally appear 1-3 days after taxane administration and last for approximately 7 days, at a wide range of sites. Recently, T-APS has been suggested to be not only an acute symptom but also a chronic symptom associated with chemotherapy-induced peripheral neuropathy (CIPN). The reported incidence of T-APS varies among studies, possibly owing to differences in observation points, evaluation methods, taxane administration methods, concomitant medications, or patient factors. Several factors, such as high taxane dose, paclitaxel use, metastatic setting, breast cancer, younger age, and co-administration of pegfilgrastim, are associated with symptom development. Several findings regarding T-APS management, such as prophylaxis using corticosteroids, Shakuyaku-Kanzo-to, and non-steroidal anti-inflammatory drugs (NSAIDs), are present. Corticosteroids for several days after taxane administration dose-dependently prevents and attenuates T-APS although we should be cautious about its longer administration. Prophylactic administration of Shakuyaku-Kanzo-to, a herbal compound, may be useful, although prescriptions are only available in limited areas. Etoricoxib, a selective cyclooxygenase-2 inhibiting NSAID, also reduces the incidence and severity of T-APS. Additionally, its prophylactic administration decreases CIPN. In contrast, evidence of symptomatic medication is limited. Taxanes are key chemotherapeutic agents used in the treatment of several types of cancer; therefore, further assessment of mechanisms of action and treatment of T-APS is necessary.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"187-196"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility Sparing Medical Management Options in Gynecologic Cancers.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1007/s11864-025-01299-4

Ana Kouri, Janelle P Darby

{"title":"Fertility Sparing Medical Management Options in Gynecologic Cancers.","authors":"Ana Kouri, Janelle P Darby","doi":"10.1007/s11864-025-01299-4","DOIUrl":"10.1007/s11864-025-01299-4","url":null,"abstract":"Opinion statement: There is an increasing use of medical management for gynecologic cancers given the rise in neoadjuvant therapies, delayed childbearing, and use of assisted reproductive technology. Chemotherapy, albeit broadly used in most gynecologic cancers, lacks long term data with respect to its associated gonadotoxicity and potential adverse pregnancy outcomes. Immunotherapy and other targeted therapies that have demonstrated promising responses in other tumor types are increasingly being studied in gynecologic malignancies. These therapies may offer opportunities for enhanced treatment response in an effort to minimize more toxic, invasive, or surgical management approaches that could have significant negative implications on fertility. Given that some of these therapies do not represent the standard of care and currently only exist in the experimental setting, detailed counseling and careful selection of patients for fertility sparing treatment remains critical. It is reasonable for patients with early stage, low-risk endometrial cancers to attempt conservative management while establishing clear treatment objectives. Early involvement of fertility specialists is necessary in order to optimize these patients' pregnancy goals. An emphasis on lifestyle changes and in particular weight loss should also be discussed with these patients. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervix cancer patients with low-risk, small tumors shows promising results that suggest this can be a safe treatment option. Patients with advanced stage disease of any primary tumor or aggressive histology such as in many cases of ovarian cancer are not appropriate candidates for prioritization of fertility sparing treatment options. Ongoing and future studies will help to better identify appropriate patients and maximize medical management options in early-stage gynecologic cancers.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"157-166"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gynecologic Cancer Screening and Prevention: State of the Science and Practice.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-27 DOI: 10.1007/s11864-025-01301-z

C Tran, H Diaz-Ayllon, D Abulez, S Chinta, M Y Williams-Brown, N Desravines

{"title":"Gynecologic Cancer Screening and Prevention: State of the Science and Practice.","authors":"C Tran, H Diaz-Ayllon, D Abulez, S Chinta, M Y Williams-Brown, N Desravines","doi":"10.1007/s11864-025-01301-z","DOIUrl":"10.1007/s11864-025-01301-z","url":null,"abstract":"Opinion statement: Gynecological cancers, including cervical, endometrial, ovarian, and vulvovaginal cancer, have increasing incidence and mortality globally over the last three decades. In that time, there have been advances in medical therapies and paradigm shifts in surgical treatment which have resulted in a greater quality of life for patients. Clinicians have also refocused efforts to preventing gynecologic cancer. The state of screening and prevention is varied in each of the cancer types. The most comprehensive screening program and only preventable gynecological cancer is cervical cancer, which has been heavily studied since the 1900s. Cervical cytology, primary high-risk human papillomavirus (HPV) testing only, and co-testing are all effective in detecting cervical dysplasia and touted by the major medical. An additional arsenal is prevention through vaccination which has been shown to decrease cervical cancer. Unfortunately, the other gynecological cancers do not have effective screening strategies. The high rates of symptoms in endometrial cancer facilitate detection at an early stage but thus far, asymptomatic screening is only advocated in very high-risk population due to the invasive nature. Novel non-invasive mechanisms are currently under study though none have translated into clinical practice as of yet. Ovarian cancer remains the most innocuous with vague symptoms at onset resulting in late-stage diagnosis. Recommendations for prophylactic oophorectomy only apply to subsets of the population with predisposing genetic mutations. This has led to an ardent push for creative strategies such as opportunistic salpingectomy and a national genetic screening program. These efforts are in addition to the investigations underway researching radiologic, liquid biopsy, and genetic marker screening modalities for all gynecologic cancer. This review article discusses the state of screening, prevention, and recent advancements and pilot studies for each gynecological cancer.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"167-178"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0